Citius Pharmaceuticals Inc

NASDAQ:CTXR   3:53:01 PM EDT
1.02
-0.12 (-10.96%)
Regulatory, Earnings Announcements

Citius Pharmaceuticals Reports Positive Results From Recent Data Monitoring Committee Meeting For Mino-Lok Phase 3 Trial

Published: 09/29/2020 18:06 GMT
Citius Pharmaceuticals Inc (CTXR) - Citius Pharmaceuticals Reports Positive Results From Recent Data Monitoring Committee Meeting for Mino-lok Phase 3 Trial.
Citius Pharmaceuticals Inc - Dmc Makes Recommendation to Continue Trial With No Modifications and Requests an Ad Hoc Meeting in Near Future.
Citius Pharmaceuticals Inc - Dmc Members Stated That They Did Not Find Any Safety Signals.
Citius Pharmaceuticals Inc - Dmc Further Requested to Have an Ad Hoc Meeting in Near Future.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.17

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.20

More details on our Analysts Page.